• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Alexza to Present AZ-001 Phase IIa Clinical Data at the American Headache Society Meeting

Posted on: Monday, 12 June 2006, 21:00 CDT

PALO ALTO, Calif., June 12 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it will present at the 48th annual American Headache Society meeting the results of a Phase IIa clinical trial of Staccato(TM) Prochlorperazine (AZ-001) for the acute treatment of migraine headache. The poster presentation, "Inhaled prochlorperazine in patients having an acute migraine attack" (Abstract F51) will be available for viewing at the meeting at the Hyatt Regency Century Plaza Hotel in Los Angeles, California on Friday, June 23, 2006 from 10:00 a.m. to 4:00 p.m. James V. Cassella, PhD, Alexza Senior Vice President, Research and Development will be presenting the poster from 12:30 p.m. to 1:30 p.m. on Friday, June 23, 2006.

Alexza is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(TM) system, vaporizes unformulated drug compound to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has four product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain.

Safe Harbor Statement

The anticipated presentation may contain forward-looking statements that involve significant risks and uncertainties, including those potentially discussed in the presentation and others that can be found in the "Risk Factors" section of Alexza's Registration Statement on Form S-1, as amended (File No. 333-130644), and Alexza's periodic reports on Form 10-Q and Form 8-K. Alexza does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release or the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.

Alexza Pharmaceuticals, Inc.

CONTACT: James V. Cassella, PhD, Senior Vice President, Research &Development of Alexza Pharmaceuticals, Inc., +1-650-687-3900, orjcassella@alexza.com

Web site: http://www.alexza.com/

Source: PRNewswire-FirstCall

More News in this Category